Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

# PF-03814735

## Catalog No: tcsc0684

### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

### Specifications

**CAS No:**
942487-16-3

**Formula:**
$C_{23}H_{25}F_3N_6O_2$

**Pathway:**
Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Epigenetics

**Target:**
VEGFR;Aurora Kinase;Aurora Kinase

**Purity / Grade:**
>98%

**Solubility:**
DMSO : ≥ 47 mg/mL (99.06 mM)

**Observed Molecular Weight:**
474.48

## Product Description

PF-03814735 is a potent, orally available and reversible **aurora A** and **aurora B** inhibitor with **$IC_{50}$**s of 0.8 and 0.5 nM, respectively.

IC50 & Target: IC50: 0.8 nM (aurora 1), 5 nM (aurora 2)[1]

***In Vitro:***

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

In intact cells, the inhibitory activity of PF-03814735 on the Aurora1 and Aurora2 kinases reduces levels of phospho-Aurora1, phosphohistone H3, and phospho-Aurora2. PF-03814735 produces a block in cytokinesis, resulting in inhibition of cell proliferation and the formation of polyploid multinucleated cells[1]. Small cell lung cancer (SCLC) and, to a lesser extent, colon cancer lines are very sensitive to PF-03814735. The status of the Myc gene family and retinoblastoma pathway members significantly correlates with the efficacy of PF-03814735[2].

***In Vivo:*** Once-daily oral administration of PF-03814735 to mice bearing human xenograft tumors produces a reduction in phosphohistone H3 in tumors at doses that are tolerable and that result in significant inhibition of tumor growth. The combination of PF-03814735 and docetaxel in xenograft mouse tumor models shows additive tumor growth inhibition[1]. PF-03814735 is much more effective in NCI-H82 xenografts when administered on a weekly dosing schedule at 80 mg/kg compared with a daily schedule at 15 mg/kg. PF-03814735 delayed growth by 23.5 days on the weekly schedule, which corresponds to 0.9 logs of net cell kill during the course of treatment[2].